Entasis Therapeutics Holdings Inc.
DelistedCIK 1724344fmd_0E63VZ9ZNWRFVK7371N814EF87Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Mar 31, 2022, 19 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
| Total revenues | – | 5 | 7 | – | – |
| Research and development | 26 | 33 | 40 | 41 | 37 |
| Total operating expenses | 31 | 43 | 54 | 54 | 52 |
| Operating income | (31) | (38) | (47) | (54) | (52) |
| Income before taxes | (30) | (32) | (43) | (50) | (47) |
| Income tax expense | – | 0 | 1 | 0 | – |
| Net income from continuing operations | – | (33) | (44) | (50) | – |
| Net income | (30) | (33) | (44) | (50) | (47) |
| Net income to common shareholders | (30) | (42) | (44) | (50) | (47) |